Pluvicto

Chemical Namelutetium (177Lu) vipivotide tetraxetan
Dosage FormInjection (intravenous; 1000 MBq/mL (27 mCi/mL))
Drug ClassRadioactive therapeutic agents
SystemMale reproductive
CompanyAdvanced Accelerator Applications
Approval Year2022

Indication

  • For the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy
Last updated on 4/27/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pluvicto (lutetium (177Lu) vipivotide tetraxetan) Prescribing Information. 2022Advanced Accelerator Applications USA, Inc., Millburn, NJ
Document TitleYearSource
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. 2021The New England Journal of Medicine